Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: A cost-effectiveness analysis

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel et al. · New England Journal of Medicine · 2006 · 2.6K citations · Full text

Medicine, Gynecology, Oncology +14

Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer et al. · Journal of Clinical Oncology · 2003 · 2.1K citations

Medicine, Gynecology, Oncology +17

A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer

Andreas du Bois · JNCI Journal of the National Cancer Institute · 2003 · 1.1K citations · Full text

Medicine, Gynecology, Oncology +17

Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis

R.E. Bristow · Journal of Clinical Oncology · 2002 · 877 citations

Medicine, Oncology, Surgery +17

Economic foundations of cost-effectiveness analysis

Alan M. Garber, Charles E. Phelps · Journal of Health Economics · 1997 · 768 citations · Full text

Pharmacy, Economics, Pharmacoeconomics +17